FR2407720A1 - Oral sustained-action capsule formulations - of drug and excipient which swells in contact with digestive juices - Google Patents
Oral sustained-action capsule formulations - of drug and excipient which swells in contact with digestive juicesInfo
- Publication number
- FR2407720A1 FR2407720A1 FR7733495A FR7733495A FR2407720A1 FR 2407720 A1 FR2407720 A1 FR 2407720A1 FR 7733495 A FR7733495 A FR 7733495A FR 7733495 A FR7733495 A FR 7733495A FR 2407720 A1 FR2407720 A1 FR 2407720A1
- Authority
- FR
- France
- Prior art keywords
- swells
- excipient
- contact
- drug
- digestive juices
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 230000001079 digestive effect Effects 0.000 title abstract 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 title abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 title abstract 2
- 230000002459 sustained effect Effects 0.000 title abstract 2
- 239000007963 capsule composition Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 2
- KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 abstract 2
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 229960001132 naftidrofuryl Drugs 0.000 abstract 2
- 230000008961 swelling Effects 0.000 abstract 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 239000005995 Aluminium silicate Substances 0.000 abstract 1
- 241000416162 Astragalus gummifer Species 0.000 abstract 1
- 229920002907 Guar gum Polymers 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920001615 Tragacanth Polymers 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 235000012211 aluminium silicate Nutrition 0.000 abstract 1
- 239000008119 colloidal silica Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000007903 gelatin capsule Substances 0.000 abstract 1
- 239000000665 guar gum Substances 0.000 abstract 1
- 235000010417 guar gum Nutrition 0.000 abstract 1
- 229960002154 guar gum Drugs 0.000 abstract 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 229960000564 nitrofurantoin Drugs 0.000 abstract 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 abstract 1
- 235000010487 tragacanth Nutrition 0.000 abstract 1
- 239000000196 tragacanth Substances 0.000 abstract 1
- 229940116362 tragacanth Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
Oral compsns. with sustained activity comprising the active drug and an excipient which swells in contact with digestive juices, this being =45% w/w of the compsn., contained in hard gelatin capsules. The compsns. may contain drugs such as aspirin, nitrofurantoin and naftidrofuryl. Swelling agents include guar gum, tragacanth and hydroxypropylmethylcellulose. A preferred agent with aspirin is 40-45% w/w of hydroxy-propylmethylcellulose; for naftidrofuryl 20-25% w/w of swelling agent. Conventional additives such as lubricants and fillers may be used, e.g. magnesium stearate, lactose kaolin, colloidal silica.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7733495A FR2407720A1 (en) | 1977-11-08 | 1977-11-08 | Oral sustained-action capsule formulations - of drug and excipient which swells in contact with digestive juices |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7733495A FR2407720A1 (en) | 1977-11-08 | 1977-11-08 | Oral sustained-action capsule formulations - of drug and excipient which swells in contact with digestive juices |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2407720A1 true FR2407720A1 (en) | 1979-06-01 |
Family
ID=9197364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7733495A Withdrawn FR2407720A1 (en) | 1977-11-08 | 1977-11-08 | Oral sustained-action capsule formulations - of drug and excipient which swells in contact with digestive juices |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2407720A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4717713A (en) * | 1983-10-31 | 1988-01-05 | Research Corporation | Controlled release liquid pharmaceutical |
| AT385200B (en) * | 1986-07-22 | 1988-02-25 | Kwizda Fa F Johann | Process for the production of tablets with delayed release characteristics of medicinal substances |
| AT398165B (en) * | 1986-06-16 | 1994-10-25 | Procter & Gamble Pharma | METHOD FOR PRODUCING A PHARMACEUTICAL CAPSULE FOR ORAL ADMINISTRATION WITH DELAYED ACTIVE SUBSTANCE RELEASE OR. COMBINED DELAYED / RAPID RELEASE OF ACTIVE SUBSTANCE |
| AT398166B (en) * | 1986-06-16 | 1994-10-25 | Procter & Gamble Pharma | METHOD FOR PRODUCING A PHARMACEUTICAL CAPSULE FOR THE ORAL ADMINISTRATION OF NITROFURANTOIN (SALTS, HYDRATES, COMPLEXES) |
| GB2378693A (en) * | 2001-06-16 | 2003-02-19 | Gursharan Moonga | Capsules for medicaments, beverages, food colourings and flavours |
| FR3070010A1 (en) * | 2017-08-02 | 2019-02-15 | Belles Feuilles | METHOD AND SYSTEM FOR CONDITIONING A COMPOSITION OF DRY EXTRACTS OF PLANTS, AND COMPOSITION OF DRY EXTRACTS OF PLANTS THUS IMPLEMENTED. |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3247066A (en) * | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
| FR1468716A (en) * | 1964-06-19 | 1967-02-10 | Ciba Geigy | Process for preparing drugs in the form of beads |
| DE1445105A1 (en) * | 1959-10-01 | 1969-01-09 | Merck & Co Inc | Process for the manufacture of a pharmaceutical carrier |
| US3427378A (en) * | 1965-02-12 | 1969-02-11 | American Cyanamid Co | Sustained release encapsulated formula |
| LU61171A1 (en) * | 1969-06-24 | 1970-08-26 | ||
| US3574820A (en) * | 1968-01-08 | 1971-04-13 | Upjohn Co | Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix |
| FR2118492A5 (en) * | 1970-12-19 | 1972-07-28 | Friedrich & Kaufmann Efeka |
-
1977
- 1977-11-08 FR FR7733495A patent/FR2407720A1/en not_active Withdrawn
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445105A1 (en) * | 1959-10-01 | 1969-01-09 | Merck & Co Inc | Process for the manufacture of a pharmaceutical carrier |
| US3247066A (en) * | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
| FR1468716A (en) * | 1964-06-19 | 1967-02-10 | Ciba Geigy | Process for preparing drugs in the form of beads |
| US3427378A (en) * | 1965-02-12 | 1969-02-11 | American Cyanamid Co | Sustained release encapsulated formula |
| US3574820A (en) * | 1968-01-08 | 1971-04-13 | Upjohn Co | Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix |
| LU61171A1 (en) * | 1969-06-24 | 1970-08-26 | ||
| FR2118492A5 (en) * | 1970-12-19 | 1972-07-28 | Friedrich & Kaufmann Efeka |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4717713A (en) * | 1983-10-31 | 1988-01-05 | Research Corporation | Controlled release liquid pharmaceutical |
| AT398165B (en) * | 1986-06-16 | 1994-10-25 | Procter & Gamble Pharma | METHOD FOR PRODUCING A PHARMACEUTICAL CAPSULE FOR ORAL ADMINISTRATION WITH DELAYED ACTIVE SUBSTANCE RELEASE OR. COMBINED DELAYED / RAPID RELEASE OF ACTIVE SUBSTANCE |
| AT398166B (en) * | 1986-06-16 | 1994-10-25 | Procter & Gamble Pharma | METHOD FOR PRODUCING A PHARMACEUTICAL CAPSULE FOR THE ORAL ADMINISTRATION OF NITROFURANTOIN (SALTS, HYDRATES, COMPLEXES) |
| AT385200B (en) * | 1986-07-22 | 1988-02-25 | Kwizda Fa F Johann | Process for the production of tablets with delayed release characteristics of medicinal substances |
| GB2378693A (en) * | 2001-06-16 | 2003-02-19 | Gursharan Moonga | Capsules for medicaments, beverages, food colourings and flavours |
| FR3070010A1 (en) * | 2017-08-02 | 2019-02-15 | Belles Feuilles | METHOD AND SYSTEM FOR CONDITIONING A COMPOSITION OF DRY EXTRACTS OF PLANTS, AND COMPOSITION OF DRY EXTRACTS OF PLANTS THUS IMPLEMENTED. |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE8304393D0 (en) | CONTROLLED RELEASE NAPROXEN AND NAPROXEN SODIUM TABLETS | |
| SE9500422D0 (en) | New oral pharmaceutical dosage forms | |
| SI0642788T1 (en) | Tramadol salt containing medicaments with sustained release of the active ingredient | |
| AU1227899A (en) | Osmotic medicament releasing system | |
| PT841903E (en) | ORAL PHARMACEUTICAL COMPOSITION CONTAINING ACTIVE ANTIMICROBIAL AGENTS AND PANTOPRAZOLE WITH DEFERRED LIBERATION | |
| FR2613224B1 (en) | EXTENDED RELEASE BILAYER DOSAGE FORM | |
| FI883785A7 (en) | Capsule for inhalation of a pharmaceutically active agent of a drug substance. | |
| AU7143796A (en) | Controlled release matrix for pharmaceuticals | |
| MY112915A (en) | Multiple unit tableted dosage form 1 | |
| ES2141380T3 (en) | METHOD FOR THE MANUFACTURE OF A COATED TABLET, WITH POINTED CORE. | |
| CO5070571A1 (en) | PHARMACEUTICAL MOXIFLOXACINE PREPARATION | |
| MY115433A (en) | Film coated tablet of paracetamol and domperidone. | |
| RU95102924A (en) | PHARMACEUTICAL PRODUCT FOR ORAL USE ON THE BASIS OF RALOXIFEN OR ITS DERIVATIVES | |
| ZA879173B (en) | Therapeutic agents | |
| FR2407720A1 (en) | Oral sustained-action capsule formulations - of drug and excipient which swells in contact with digestive juices | |
| DK0615441T3 (en) | Ibuprofen-containing drug for emergency use and its use | |
| AU1244199A (en) | Tablets to be crunched or sucked, comprising iron as active principle | |
| EP0302714A3 (en) | Pharmaceutical composition for treatment of bone-wasting diseases | |
| PL316079A1 (en) | Antiussive composition containing an antitussive agent and benzidamine | |
| CA2255064A1 (en) | Potassium, sodium and tris oxaprozin salt pharmaceutical formulations | |
| Lapierre et al. | Dyskinesia associated with amoxapine antidepressant therapy: a case report. | |
| SE8204288D0 (en) | APAP ANTICIDUM composition | |
| FI963567A0 (en) | The diclofenacs containing prolonged-release tablets | |
| AU5284286A (en) | Antiinflammatory composition of inositol and piroxicam | |
| ES8603262A1 (en) | Oral solid pharmaceutical form with sequential action for the administering of drugs with ulcerogenic side effect. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |